This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=95 http://www.lsis.com/goto/r95/rss 2012-02-05T11:11:00+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Mass spectrometry imaging has proven to be a complementary assay to the traditional labeled-compound studies employed in drug research and development. However, there has been limited examination of the technical limitations of the technique with respect to small molecule stability in samples. |-| Rapid Commun Mass Spectrom. |-| Goodwin RJ, Iverson SL, Andren PE. |-| Medical Mass Spectrometry, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Global Distribution (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Medicinal chemistry makes a vital contribution to small molecule drug discovery, and the quality of it contributes directly to research effectiveness as well as to downstream costs, speed and survival in development. In recent years, the discipline of medicinal chemistry has evolved and witnessed many noteworthy contributions that propose and offer potential improvements to medicinal chemistry practice; however, the impact of these ideas is limited by their acceptance and deployment into (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 N-phenylanthranilic acid is a chloride channel blocker that causes renal papillary necrosis in rats. Studies were conducted in two strains of male rats to evaluate novel biomarkers of nephrotoxicity. Han-Wistar rats were given daily oral doses of 50, 350, or up to 700 mg/kg/day of NPAA, and Sprague-Dawley rats were given 50 or 400 mg/kg/day of NPAA. Rats were euthanized on days 8 and 15. The candidate kidney injury biomarkers renal papillary antigen-1 (RPA-1, for collecting duct injury), (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics. Historically optimisation of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung. Recent efforts have led to an increased understanding of lung concentrations and how (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 A novel arylsulfonamide-containing series of compounds represented by 1, discovered by highthroughput screening, inhibit the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). X-ray structure determination confirmed that inhibitor binds at the site occupied by acetyl-CoA, indicating that series is competitive with this substrate. This letter documents our early hit-to-lead evaluation of the chemical series and some of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 The desired outcome in schizophrenia treatment has evolved from symptom management to maximization of quality of life and functional recovery. The aim of this study was to assess the relationship between a specific well-being measure, the Subjective Well-being under Neuroleptic Scale - short version (SWN-K), and the SF-36 Health Survey as a generic quality of life measure. |-| Patient Prefer Adherence. |-| Mauriño J, Cordero L, Ballesteros J. |-| AstraZeneca Medical Department, Madrid, Spain. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 The health challenges of China and Asia offer big opportunities for multinational pharma companies. Cases of chronic diseases, such as diabetes, are on the rise in the region, as are lung, gastric, and liver cancers. China alone is likely to be the world s third-largest pharmaceutical market by this year, with sales of more than $50 billion. AstraZeneca, the largest multinational pharmaceutical company in China s prescription market, has positioned itself to take advantage of this growth it (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 AKT is a key node in the most frequently de-regulated signaling network in human cancer. AZD5363, a novel pyrrolopyrimidine derived compound, inhibited all AKT isoforms with a potency of text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 LONDON-(BUSINESS WIRE)-Regulatory News: AstraZeneca (STO:AZN)(LSE:AZN): Revenue for the full year was down 2 percent at constant exchange rates (CER) at $33,591 million. -Strong double-digit sales growth at CER for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10 percent at CER in the fourth quarter and for the full year. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 Drug maker AstraZeneca PLC said it will cut another 7,300 jobs as it warned Thursday of a tough year ahead, due to government spending cuts on healthcare and stiff competition, even as it reported a 24 percent increase in 2011 profits. The Anglo-Swedish company said its full-year profit was $10 billion, up from $8.1 billion a year earlier. The profit advance was helped heavily by a $1.5 billion gain from the sale of its dental subsidiary, Astra Tech. The company said revenue this year will be (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 PURPOSE: Disproportionality analysis is an important tool for interpreting spontaneous adverse event reports in pharmacovigilance. There exist a variety of disproportionality measures (DPMs) for use in safety signaling; however, it is not always clear which method is best suited for a particular need. A framework for comparing the various DPMs is necessary to fully understand the consequences of quantitative signal detection implementation decisions. Here, the mathematical relationship between (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 HAYWARD, Calif.-(BUSINESS WIRE)- Impax Pharmaceuticals, the branded products business unit of Impax Laboratories, Inc. (NASDAQ: IPXL - News), announced today that it has licensed from AstraZeneca the exclusive United States (U.S.) commercial rights to Zomig (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations. As part of a Distribution, License, Development and Supply Agreement, Impax will also have non-exclusive rights to develop new products containing (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 An oral, peripherally restricted CB1/CB2 agonist could provide an interesting approach to treat chronic pain by harnessing the analgesic properties of cannabinoids but without the well-known central side effects. ?-Carbolines are a novel class of potent mixed CB1/CB2 agonists characterized by attractive physicochemical properties including high aqueous solubility. Optimization of the series has led to the discovery of 29, which has oral activity in a rat inflammatory pain model and limited (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 STOCKHOLM, Sweden-(BUSINESS WIRE)-Leading contract research provider, Syntagon, is delighted to announce that it has entered into a collaborative agreement with world-class Quality Assurance (QA) expert George Köllner. George brings with him more than 20 years experience from the pharma industry. He has served as Director of Quality Assurance at AstraZeneca where he led the development and implementation of modern Quality Assurance systems in API Process Development. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=95 United States Patent: 8106063 |-| Title: Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |-| Inventors: Ebden; Mark (Loughborough, GB), Meghani; Premji (Loughborough, GB), Bennion; Colin (Loughborough, GB), Cook; Anthony Ronald (Loughborough, GB), Bonnert; Roger Victor (Loughborough, GB) |-| Assignee: AstraZeneca AB (Sodertalje, SE) |-| A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 AstraZeneca Plc (AZN), the U.K. s second- biggest drugmaker, is set to announce more job cuts after beginning a cost-cutting program in 2010, the Sunday Times reported today, without citing anyone. Two years ago, chief executive David Brennan said more than 10,000 jobs would be lost by 2014, the newspaper said. The target may be extended significantly when the company announces its annual results on Feb. 2, the newspaper said. The drugmaker may spend more than $3 billion on buying back shares (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 BACKGROUND: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass grafting (CABG) surgery. The objective of this study was to determine the impact of POAF on both short- and long-term mortality following isolated CABG. HYPOTHESIS: POAF is associated with a poorer short and long-term mortality following CABG. METHODS: We retrospectively analyzed the preoperative and operative data of 6728 consecutive patients undergoing a first isolated CABG. RESULTS: The (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Hand-held electronic devices may provide a simple reproducible means by which quality of life (QOL) may be documented in patients with cancer. However, the QOL scales that are routinely used were originally validated when used with paper and pencil data collection. Patient-reported outcomes acquired using hand-held electronic devices (electronic patient-reported outcomes [e-PRO]) may not be the same as those acquired using paper and pencil, so validation of this method of data collection is (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 : Atrial fibrillation (AF) represents a significant burden on healthcare resources. This study aimed to (i) identify key determinants for treatment choices in AF; (ii) analyze impacts of AF treatment on patient satisfaction and compliance; and (iii) analyze impacts of AF treatment on physician satisfaction and willingness to prescribe. |-| Patient. |-| Edvardsson N, Westlund A, Thimell M, Rise K, Todoran A, Aberg Kurén T, Kindblom J, Almgren O. |-| 1 Sahlgrenska Academy at Sahlgrenska (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 BACKGROUND: Aromatase inhibitors have shown increased efficacy compared with tamoxifen in postmenopausal early breast cancer. We aimed to assess the efficacy and safety of anastrozole versus tamoxifen in premenopausal women receiving goserelin for early breast cancer in the neoadjuvant setting. METHODS: In this phase 3, randomised, double-blind, parallel-group, multicentre study, we enrolled premenopausal women with oestrogen receptor (ER)-positive, HER2-negative, operable breast cancer with (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Toxicol Pathol. |-| Bolton S, Hassall D, Hildebrand D, Brück W, Huang JK, Pluchino S, McKevitt T, Parry J, McFarlane M, Fagg R, Roulois A. |-| 1Department of Pathology, Safety Assessment UK, AstraZeneca R&D, Leicestershire, UK. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Sickle cell disease is one of the most common inherited diseases in the world, and can cause haemolytic anaemia, vaso-occlusive crises and dysfunction in virtually any organ system in the body. Surgical procedures are often required. Blood transfusion regimens can be used preoperatively in an attempt to increase transport of oxygen around the body and dilute the sickled red blood cells, thus reducing the risk of vaso-occlusion. |-| Cochrane Database Syst Rev. |-| Hirst C, Williamson L. |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 The bacterial ?-transaminase from Chromobacterium?violaceum (Cv-?TA, EC2.6.1.18) catalyses industrially important transamination reactions by use of the coenzyme pyridoxal 5'-phosphate (PLP). Here, we present four crystal structures of Cv-?TA: two in the apo form, one in the holo form and one in an intermediate state, at resolutions between 1.35 and 2.4?Å. The enzyme is a homodimer with a molecular mass of ?100?kDa. Each monomer has an active site at the dimeric interface that (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Modifications to a series of potent and selective substituted 1-(3,3-diphenylpropyl)-piperidine phenylacetamide CCR5 antagonists were explored with the aim of reducing affinity at the hERG cardiac ion channel. Replacement of one aromatic ring in the diphenylpropyl region with less lipophilic, saturated heterocyclic rings and subsequent optimisation of the other phenyl ring led to the identification of clinical compound AZD5672 which retained excellent potency while reducing hERG affinity. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 : As upper gastrointestinal (GI) symptoms are common with the use of low-dose aspirin (low-dose acetylsalicylic acid [LDASA]; 75-325?mg/day), this exploratory qualitative study evaluated the upper GI symptom experience and attribution of symptoms among patients taking LDASA for coronary artery disease (CAD) or known CAD risk factors. |-| Patient. |-| Margolis MK, Halling K, Sörstadius E, N� sdal J, Manson S, Coyne K. |-| 1 United BioSource Corporation, Center for Health Outcomes Research, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 A series of structurally unique Smac mimetics that act as antagonists of inhibitor of apoptosis proteins (IAPs) has been discovered. While most previously described Smac mimetics contain the proline ring (or a similar cyclic motif) found in Smac, a key feature of the compounds described herein is that this ring has been removed. Despite this, compounds in this series potently bind to cIAP1 and elicit the expected phenotype of cIAP1 inhibition in cancer cells. Marked selectivity for cIAP1 over (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 LEIDEN, Netherlands-(BUSINESS WIRE)- Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised ¬23 million in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. David Mott, General Partner of NEA, will join Prosensa (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=95 United States Patent: 8101623 |-| Title: Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |-| Inventors: Luke; Richard William Arthur (Macclesfield, GB), Matusiak; Zbigniew Stanley (Macclesfield, GB) |-| Assignee: AstraZeneca AB (Sodertaje, SE) |-| The invention relates to a novel group of compounds of Formula (I) or salts thereof: #STR00001# wherein Y, Z.sup.1, Z.sup.2, R.sup.1, R.sup.4, R.sup.5 and n are as described in the specification, which may be useful in the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 San Francisco Business Times by Ron Leuty, Reporter When Howard Robin took over as president and CEO of Nektar Therapeutics Inc. . in early 2007, the company was based in San Carlos with a high payroll and, essentially, one product in the form of the inhaled insulin drug-device Exubera. Since Pfizer Inc. . pulled Exubera later that year, Nektar (NASDAQ: NKTR) has moved to San Francisco, shed workers, cut expenses and developed several programs, ranging from breast cancer to pain. I take a (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 DUBLIN, Ohio-(BUSINESS WIRE)-Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) today announced that the Banner Alzheimer s Institute, Phoenix, AZ, made two presentations of results from an AstraZeneca-sponsored study on the assessment of Navidea s late-stage radiopharmaceutical imaging candidate, AZD4694, at the 6th Annual Human Amyloid Imaging Meeting (HAI), in Miami, FL. In December 2011, Navidea in-licensed the worldwide exclusive rights to AZD4694 from AstraZeneca, now being developed (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 AstraZeneca Plc (AZ) s pledge to avoid big acquisitions may be tested after setbacks for three of the company s most promising drugs in development. Chief Executive Officer David Brennan hasn t announced an acquisition of more than $1 billion since buying MedImmune Inc. in 2007 for about $15.2 billion, and the company says it s not looking for another deal of that size. Analysts at Credit Suisse AG and JPMorgan Chase & Co. have said AstraZeneca may undertake a bigger takeover to replace (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 PRINCETON, N.J. & WILMINGTON, Del.-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapagliflozin for the treatment of type 2 diabetes in adults. The complete response letter requests additional clinical data to allow a better assessment of the benefit-risk profile for dapagliflozin. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Stroke prevention with appropriate thromboprophylaxis still remains central to the management of atrial fibrillation (AF). Nonetheless, stroke risk in AF is not homogeneous, but despite stroke risk in AF being a continuum, prior stroke risk stratification schema have been used to 'artificially' categorise patients into low, moderate and high risk stroke strata, so that the patients at highest risk can be identified for warfarin therapy. Data from recent large cohort studies show that by being (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 This article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies. There is (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Insulin Sensitivity is an important parameter for the management of Diabetes. It can be derived for a particular patient using data derived from some glucose challenge tests using measured glucose and insulin levels at various times. Whilst a useful approach, deriving insulin sensitivities to inform insulin dosing in other settings such as Intensive Care Units can be more challenging - especially as insulin levels have to be assayed in a laboratory, not at the bedside. This paper investigates (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 A number of novel urinary biomarkers have been identified and partially qualified for use as markers for renal injury in rats. To date, all evaluation studies have been made using 18 to 24 hour collection periods. However, shorter, more welfare friendly, urine collection periods are also used in industry. In this article, we quantify urinary biomarker concentration in serial paired sequential short and long urine collections from male rats administered varying concentrations of cisplatin. We (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 BOULDER, Colo.-(BUSINESS WIRE)-Array BioPharma Inc. (NASDAQ: ARRY) today announced that Robert E. Conway has resigned as Chief Executive Officer and a Director for personal reasons. The Board has appointed Kyle Lefkoff, Chairman of the Board, to serve as Executive Chairman. In this capacity, Mr. Lefkoff will oversee the Company in the interim and lead the effort to identify a new Chief Executive Officer. œAs Executive Chairman,  Mr. Lefkoff stated, œI will be focused on working with the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 OBJECTIVES: Gastroesophageal reflux disease (GERD) is present in pediatric patients when reflux of gastric contents causes troublesome symptoms and/or complications. This study evaluates the efficacy and safety of esomeprazole in infants aged 1-11 months with GERD. METHODS: In this multicenter randomized, double-blind, placebo-controlled, parallel group, treatment-withdrawal study, infants received open-label, weight-adjusted doses of esomeprazole (2.5-10?mg) once daily for 2 weeks. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 The Ireland-Claisen [3,3]-sigmatropic rearrangement has been used to access biologically important ?,?'-dihydroxy ?-amino acids. The rearrangement reported is highly stereoselective and offers excellent levels of remote stereocontrol. This strategy has been used to synthesize the natural immunosuppressant mycestericin G and ent-mycestericin G, allowing for a revision of absolute configuration of this natural product. |-| Org Lett. |-| Fairhurst NW, Mahon MF, Munday RH, Carbery DR. |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Objectives? To design and evaluate a national web-based dispensing error reporting system for all Swedish pharmacies, replacing the currently used paper-based system. Methods? A working group designed the new system. The number of reports before (1999-2003) and after (2004-2005) introduction was studied in a descriptive analysis. The completeness of reports was evaluated through the study of 100 randomly selected reports from the third quarter of 2003 and 2004 from each system. Evaluation (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Background: Bronchodilator therapy is central to the symptomatic management of chronic obstructive pulmonary disease (COPD), and treatment with short-acting bronchodilators is recommended in patients with mild COPD. Objective: This study aimed to evaluate the onset of effect of single-dose formoterol 9?g versus single-dose salmeterol 50?g in patients with moderate COPD. Methods: In this multicentre, double-blind, double-dummy, placebo-controlled, three-way single-dose crossover study, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Context:Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding.Objectives:Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components.Design and Setting:This was a 24-wk, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 A key figure in a scandal in which AstraZeneca was indicted in Serbia over allegations of offering bribes to physicians has committed suicide. Nenad Borojevic, who was the former director of the Serbian Institute of Oncology and Radiology Nenad Borojevic, was found hanging from a tree in a forest in Belgrade, according to media reports (read here and here). text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 Novartis AG plans to axe nearly 2,000 of its U.S. workforce ahead of the patent loss of top-selling blood pressure drug Diovan there and will take a $900 million charge after another of its key drugs failed to live up to expectations. Novartis is the latest in a long line of global drugmakers to cut its sales force as the industry faces its biggest wave of patent expiries ever. The Swiss drugmaker's news comes just weeks after AstraZeneca said it was slashing nearly a quarter of its U.S. sales (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 1.?The aim was to investigate effects of nabilone on capsaicin-induced pain and hyperalgesia, and on biomarkers of cannabinoid CNS effects. 2.?A randomized, double-blind, placebo-controlled, crossover study was conducted in 30 healthy male volunteers receiving single doses of nabilone 1, 2 or 3 mg. Pain intensity after intradermal capsaicin injections in the forearm was assessed by continuous Visual Analogue Scale (VAS, 0-100 mm). Capsaicin cream was applied to the calf to induce (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 WILMINGTON, Del.-(BUSINESS WIRE)-The AstraZeneca HealthCare Foundation announced Thursday that it is accepting online applications for the 2012 Connections for Cardiovascular HealthSM program. To qualify for a Foundation grant, US-based nonprofit 501 (c)(3) or similar organizations must be engaged in charitable work in the United States that address the program s mission of improving cardiovascular health and meet key criteria, such as: ¢Addressing cardiovascular health issues within the US (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 U.K. drug maker AstraZeneca PLC (AZN) has struck a deal with a health-care consultancy to gain further information on how its drugs are faring on the market and in hospitals, reflecting a growing need for pharmaceutical companies to prove the cost-efficiency of their products to cash-strapped governments. The U.K.'s No. 2 drug maker said the three-year venture with U.S.-based IMS Health will give it access to electronic health records, which include clinical outcome, economic and treatment (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=95 Although many imaging biomarkers have been described for cancer research, few are sufficiently robust, reliable and well-characterised to be used as routine tools in clinical cancer research. In particular, biomarkers which show that investigational therapies have reduced tumour cell proliferation, or induced necrotic or apoptotic cell death are not commonly used to support decision-making in drug development, even though such pharmacodynamic effects are common goals of many classes of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=95 London, 10 January 2012 - Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced that the Technology Strategy Board has funded a research consortium comprising of Plasticell, Pfizer (Neusentis) and the University of Sheffield, led by Cellzome. The project will develop methods of characterizing stem cells through protein fingerprints predictive of changes in stem cell behaviour. The Technology Strategy Board will (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=95 United States Patent: 8093252 |-| Title: Crystalline polymorphic form of glucokinase activator |-| Inventors: Bowden; Sharon Ann (Bristol, GB), Hoile; David Peter (Bristol, GB), Lovqvist; Karin (Molndal, SE) |-| Assignee: AstraZeneca AB (Sodertalje, SE) |-| A new polymorphic form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methy- loxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide, processes for making it and its use as an activator of glucokinase are described.